ERD

Summary report describing fundamental drug design principles and their environmental significance (D4.2.2)

Project: PREMIER

Updated at: 01-10-2024

Show more information

Project acronym PREMIER

Integration of existing GLP study data from industry partners and EPAR data (D3.1.3)

Project: PREMIER

Updated at: 01-10-2024

Show more information

Project acronym PREMIER

Periodic Reporting for period 3 - PREMIER (Prioritisation and Risk Evaluation of Medicines in the EnviRonment)

Project: PREMIER

Updated at: 01-10-2024

Show more information

Project acronym PREMIER

List of approximately 10 APIs selected for MoA-driven testing in WP1.3 (D1.1.2)

Project: PREMIER

Updated at: 01-10-2024

Show more information

Project acronym PREMIER

API prioritisation and selection for iterative assessment (D1.2.1)

Project: PREMIER

Updated at: 01-10-2024

Show more information

Project acronym PREMIER

Report on stakeholder questions and requirements and work plan for further guidance development (D4.1.1)

Project: PREMIER

Updated at: 01-10-2024

Show more information

Project acronym PREMIER

Report summarising drug discovery and development process and key attributes of tools/models (D4.2.1)

Project: PREMIER

Updated at: 01-10-2024

Show more information

Project acronym PREMIER

Inventory of APIs on the European market together with important ecotox, phys/chem and consumption data (D1.1.1)

Project: PREMIER

Updated at: 01-10-2024

Show more information

Project acronym PREMIER

Evaluation of the risk for bio-accumulation of APIs in fish via irreversible inhibition of hepatic CYPs (D2.3.2)

Project: PREMIER

Updated at: 05-04-2024

Show more information

Project acronym PREMIER

Factors Determining the Susceptibility of Fish to Effects of Human Pharmaceuticals

Project: PREMIER

Updated at: 28-02-2024

Show more information

Project acronym PREMIER

Combining predictive and analytical methods to elucidate pharmaceutical biotransformation in activated sludge

Project: PREMIER

Updated at: 28-02-2024

Show more information

Project acronym PREMIER

Systematic Handling of Environmental Fate Data for Model Development─Illustrated for the Case of Biodegradation Half-L...

Project: PREMIER

Updated at: 28-02-2024

Show more information

Project acronym PREMIER

Designing greener active pharmaceutical ingredients: Insights from pharmaceutical industry into drug discovery and devel...

Project: PREMIER

Updated at: 28-02-2024

Show more information

Project acronym PREMIER

Minimizing Experimental Testing on Fish for Legacy Pharmaceuticals

Project: PREMIER

Updated at: 28-02-2024

Show more information

Project acronym PREMIER

PREMIER ERA database architecture agreed and established (D3.1.1)

Project: PREMIER

Updated at: 31-07-2023

Show more information

Project acronym PREMIER

Project communication plan and initial toolset

Project: PREMIER

Updated at: 31-07-2023

Show more information

Project acronym PREMIER

Initial Data and Knowledge Management plan (D3.3.2)

Project: PREMIER

Updated at: 31-07-2023

Show more information

Project acronym PREMIER

A Generalized Physiologically Based Kinetic Model for Fish for Environmental Risk Assessment of Pharmaceuticals

Project: PREMIER

Updated at: 31-07-2023

Show more information

Project acronym PREMIER

GREENER Pharmaceuticals for More Sustainable Healthcare

Project: PREMIER

Updated at: 31-07-2023

Show more information

Project acronym PREMIER

Resources

Selected filters:

Summary report describing fundamental drug design principles and their environmental significance (D4.2.2)

Integration of existing GLP study data from industry partners and EPAR data (D3.1.3)

Periodic Reporting for period 3 - PREMIER (Prioritisation and Risk Evaluation of Medicines in the EnviRonment)

List of approximately 10 APIs selected for MoA-driven testing in WP1.3 (D1.1.2)

API prioritisation and selection for iterative assessment (D1.2.1)

Report on stakeholder questions and requirements and work plan for further guidance development (D4.1.1)

Report summarising drug discovery and development process and key attributes of tools/models (D4.2.1)

Inventory of APIs on the European market together with important ecotox, phys/chem and consumption data (D1.1.1)

Evaluation of the risk for bio-accumulation of APIs in fish via irreversible inhibition of hepatic CYPs (D2.3.2)

Factors Determining the Susceptibility of Fish to Effects of Human Pharmaceuticals

Combining predictive and analytical methods to elucidate pharmaceutical biotransformation in activated sludge

Systematic Handling of Environmental Fate Data for Model Development─Illustrated for the Case of Biodegradation Half-L...

Designing greener active pharmaceutical ingredients: Insights from pharmaceutical industry into drug discovery and devel...

Minimizing Experimental Testing on Fish for Legacy Pharmaceuticals

PREMIER ERA database architecture agreed and established (D3.1.1)

Project communication plan and initial toolset

Initial Data and Knowledge Management plan (D3.3.2)

A Generalized Physiologically Based Kinetic Model for Fish for Environmental Risk Assessment of Pharmaceuticals

GREENER Pharmaceuticals for More Sustainable Healthcare